Q1 Earnings Estimate for CMPX Issued By HC Wainwright

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Compass Therapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.11) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.07) EPS and FY2028 earnings at $0.85 EPS.

Several other research firms also recently weighed in on CMPX. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Piper Sandler assumed coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target for the company. Finally, Guggenheim started coverage on Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 price objective on the stock. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $2.73 on Monday. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08. The company has a market cap of $375.62 million, a price-to-earnings ratio of -7.38 and a beta of 1.17. The business’s 50 day moving average price is $2.61 and its 200-day moving average price is $1.97.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new stake in Compass Therapeutics during the fourth quarter valued at about $35,000. Tang Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after buying an additional 9,451 shares during the last quarter. MPM Bioimpact LLC raised its stake in shares of Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics during the fourth quarter valued at approximately $11,293,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.